FY2018 LHHS IPM Institute Testimony Tick-borne Disease IPM FINAL 060217

Integrated Pet Management (IPM) Institute https://ipminstitute.org submitted Tick-borne disease testimony to Congress today.  Wording is in link above.

ITM (Integrated Tick Management) seeks to manage tick habitats, incorporate pesticide sprays, and provide host-targeted strategies for deer and mice.

Excerpt below:

In 2015 alone, the estimated annual US direct and indirect medical costs, lost income and tax revenue from 380,690 new cases of Lyme disease at $10,817 per case, totaled more than $4.1 billion. Lyme disease can cause lifelong, debilitating effects in humans and animals, and in some cases, death from direct and indirect health impacts.
If additional tick-borne diseases including babesia, anaplasmosis, tularemia and Rocky Mountain spotted fever are considered, the number of cases and costs increases by 30 percent to an estimated $5.4 billion annually. Tick-borne diseases in humans are increasing in number of diseases, cases and geographic distribution in the US. Without a serious investment in cost-effective, long-term solutions to reduce tick populations, tick-borne diseases will continue to spread and costs on the population’s health and wallets will only increase.
Given these tremendous costs and impacts on human lives, resources for tick-borne disease prevention and research must be elevated to a level commensurate with other diseases. For example, in 2012 the NIH invested $112 million in hepatitis C with 1300 new cases annually, or $86,154 per new case. Similarly, there was an investment of $29 million compared to 5700 new cases of West Nile virus, or $5087 per new case. In comparison, only $25 million was invested vs. 312,000 new cases of Lyme disease, which is only $80 per new case. As Lyme disease cases rose in 2013, the NIH reduced funding to $20 million. The investments to reduce Hepatitis C and West Nile virus have been effective and provide evidence that commensurate funding would mitigate tick-borne disease.
Although tick-borne diseases have been identified as a top priority in the CDC strategic plan, investment in reducing tick populations has remained minimal. The total 2016 CDC funding line for Lyme disease was approximately $10.6 million dollars.
In particular, more resources for prevention are critically needed. All federal agency funding allocation from 2006-2010 for tick-borne disease studies totaled $368,103,780. Only 2% ($7,362,075) of that funding supported tick surveillance and environmental factors, and only 3% ($11,043,113) of that funding for tick-borne disease studies supported research on ticks.